Deutsche Bank upgraded Alvotech (ALVO) to Buy from Hold with a $14 price target The firm believes the company offers “scarcity value” in the biosimilar market, which “remains within its infancy.” Alvotech is well positioned to benefit from the sector’s opportunity, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALVO: